COVID-19 and autoimmune bullous diseases: Lessons learned.
COVID-19
Pemphigoid
Pemphigus
SARS-CoV-2
Journal
Autoimmunity reviews
ISSN: 1873-0183
Titre abrégé: Autoimmun Rev
Pays: Netherlands
ID NLM: 101128967
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
09
01
2023
accepted:
30
01
2023
pubmed:
5
2
2023
medline:
23
3
2023
entrez:
4
2
2023
Statut:
ppublish
Résumé
Both COVID-19 and autoimmune bullous diseases represent potentially life-threatening conditions. Autoimmunity has been a special focus during the COVID-19 pandemic considering the possible detrimental mutual influence between COVID-19 and autoimmune disorders as well as their supposed induction or triggering by SARS-CoV-2 vaccines. There is a growing need to assess the impact of the current pandemic particularly in patients with autoimmune bullous diseases requiring potent and long-term immunosuppressive treatments. This review provides the relevant state-of-the-art knowledge, including our own research, about immunobullous diseases in relation to COVID-19 and summarizes expert perspectives on their management throughout the pandemic.
Identifiants
pubmed: 36738951
pii: S1568-9972(23)00020-4
doi: 10.1016/j.autrev.2023.103286
pmc: PMC9893837
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103286Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Drs. Kasperkiewicz and Woodley declare no conflicts of interest.